Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Front Pharmacol ; 13: 849598, 2022.
Article in English | MEDLINE | ID: covidwho-1969055

ABSTRACT

Background: Qingfei Paidu decoction (QFPDD) has been widely used in treating coronavirus disease 2019 (COVID-19) in China. However, studies on the treatment effect of COVID-19 patients and other respiratory diseases have not been well demonstrated. Our study aims to determine the treatment effect of QFPDD in combination with conventional treatment on COVID-19 patients and other respiratory diseases. Methods: This retrospective study recruited COVID-19 patients who were treated with QFPDD for at least two courses (6 days) from seven hospitals in five provinces from January 21 to March 18 2020. Demographic, epidemiological, clinical, laboratory, computed tomography characteristics, treatment, and outcome data were collected and analyzed. The improvements in clinical symptoms before and after QFPDD treatment were compared. Results: Eight COVID-19 patients were included in this study. Of them, six were males (75.0%). The median age of the patients was 66 (60-82) years. Four patients were classified as mild and moderate cases (50.0%); there were two severe cases (25.0%) and critical cases (25.0%). The most common symptom was cough (7 [87.5%]), followed by fever (6 [75.0%]), fatigue (4 [50.0%]), asthma (4 [50.0%]), and anorexia (3 [37.5%]). Abnormal findings included decrease in neutrophils (3 [37.5%]), lymphocytes (2 [25.0%]), alkaline phosphatase (3 [37.5%]), lactic dehydrogenase (4 [50.0%]), erythrocyte sedimentation rate (2 [25.0%]), and C-reactive protein (5 [83.3%]) at admission. After one course (3 days) of QFPDD, nasal obstruction and sore throat completely disappeared, and fever (5 [83.3%]), fatigue (2 [50.0%]), and cough (2 [28.6%]) were improved. After two courses (6 days), the fever disappeared completely in all patients, and the other symptoms showed a tendency to improve. In non-severe patients, 87.5% baseline symptoms completely disappeared. In severe patients, 61.1% of the baseline symptoms completely disappeared after patients were administered QFPDD for two courses. Of the abnormal indicators, 55.6% returned to normal levels. The median duration to complete fever recovery was 1.0 day. The median durations of viral shedding and hospitalization were 10.5 and 21.5 days, respectively. None of the patients worsened and died, and no serious adverse events occurred related to QFPDD during hospitalization. Conclusion: QFPDD combined with conventional treatment improved clinical symptoms in COVID-19 patients with other respiratory diseases, and no serious adverse reactions associated with QFPDD were observed. Larger sample studies confirm our findings in the future.

2.
Chinese Journal of Integrated Traditional and Western Medicine ; 42(2):218-222, 2022.
Article in Chinese, English | CAB Abstracts | ID: covidwho-1837498

ABSTRACT

As evidence is rapidly accumulated and updated during the coronavirus disease 2019 (COVID-19) pandemic, rapid and living guidelines are needed to guide the clinical practice of Chinese medicine (CM), for which the WHO handbook of rapid guideline development should be referred to, and the characteristics of CM should be addressed. When constructing the body of evidence, we need to systematically search the studies related to COVID-19 (direct) and indirect diseases, and to collect the experience evidence from ancient documents and expert consensus, thereby maximumly presenting the advantages of CM. When the recommendations are developed, the co-existing direct and indirect evidence, as well as the co-existing research and experience evidence should be fully considered and synthesized by taking priority on whichever higher level evidence it is. The development of the rapid and living CM guidelines meets the ever-changing clinical needs during COVID-19 pandemic, and can provide CM evidence supports for decision making during public health emergencies.

3.
Curr Med Imaging ; 17(11): 1324-1329, 2021.
Article in English | MEDLINE | ID: covidwho-1574892

ABSTRACT

BACKGROUND AND AIMS: Coronavirus Disease 2019 (COVID-19) pandemic has become a global health issue. This study aimed to explore the clinical characteristics and CT imaging features of patients with COVID-19 on admission. METHODS: Consecutive patients with laboratory-confirmed COVID-19 were retrospectively recruited to this study from January 2020 to March 2020. According to the disease severity status on admission, patients were divided into two groups, the common group, and the severe group. RESULTS: Forty-four patients (F/M 20/24) who were COVID-19 positive were enrolled in this study. The most common onset symptom was fever (90.9%), followed by cough (43.2%). As for the laboratory tests, common findings included increased C reactive protein (47.7%) and erythrocyte sedimentation rate (43.2%) and decreased lymphocyte (34.1%). The frequency of decreased lymphocyte count and increased lactate dehydrogenasewas higher in the severe group (n=14) than in the common group (n=30). About 86% of patients showed typical imaging findings of COVID-19 infection, including ground-glass opacity with ill-defined margins, air bronchogram, interlobular septal thickening, and consolidation. Lesions were mainly located in the peripheral and subpleural regions with diffused distribution and multiple lung lobes were found to be affected. CONCLUSION: Fever and cough were the most common onset symptoms of COVID-19. Increased C reactive protein and erythrocyte sedimentation rate were the most common laboratory findings. Typical signs of chest CT imaging of COVID-19 included ground-glass opacity with ill-defined margins, air bronchogram, interlobular septal thickening, and consolidation.


Subject(s)
COVID-19 , Humans , Retrospective Studies , SARS-CoV-2
4.
Pharmacol Res ; 161: 105290, 2020 11.
Article in English | MEDLINE | ID: covidwho-1318948

ABSTRACT

The coronavirus disease 2019 (COVID-19) epidemic has been almost controlled in China under a series of policies, including "early diagnosis and early treatment". This study aimed to explore the association between early treatment with Qingfei Paidu decoction (QFPDD) and favorable clinical outcomes. In this retrospective multicenter study, we included 782 patients (males, 56 %; median age 46) with confirmed COVID-19 from 54 hospitals in nine provinces of China, who were divided into four groups according to the treatment initiation time from the first date of onset of symptoms to the date of starting treatment with QFPDD. The primary outcome was time to recovery; days of viral shedding, duration of hospital stay, and course of the disease were also analyzed. Compared with treatment initiated after 3 weeks, early treatment with QFPDD after less than 1 week, 1-2 weeks, or 2-3 weeks had a higher likelihood of recovery, with adjusted hazard ratio (HR) (95 % confidence interval [CI]) of 3.81 (2.65-5.48), 2.63 (1.86-3.73), and 1.92 (1.34-2.75), respectively. The median course of the disease decreased from 34 days to 24 days, 21 days, and 18 days when treatment was administered early by a week (P < 0.0001). Treatment within a week was related to a decrease by 1-4 days in the median duration of hospital stay compared with late treatment (P<0.0001). In conclusion, early treatment with QFPDD may serve as an effective strategy in controlling the epidemic, as early treatment with QFPDD was associated with favorable outcomes, including faster recovery, shorter time to viral shedding, and a shorter duration of hospital stay. However, further multicenter, prospective studies with a larger sample size should be conducted to confirm the benefits of early treatment with QFPDD.


Subject(s)
COVID-19/drug therapy , Drugs, Chinese Herbal/therapeutic use , Adult , Aged , Aged, 80 and over , China , Cohort Studies , Female , Follow-Up Studies , Humans , Length of Stay , Male , Middle Aged , Time-to-Treatment , Treatment Outcome , Young Adult
5.
J Tradit Chin Med ; 40(6): 891-896, 2020 12.
Article in English | MEDLINE | ID: covidwho-952512

ABSTRACT

OBJECTIVE: To summarize the evidence from Traditional Chinese Medicine (TCM) practice in the treatment of coronavirus disease 2019 (COVID-19) and provide timely clinical practice guidance. METHODS: The guidelines were developed in accordance with the World Health Organization rapid guideline process. The evidence on TCM for COVID-19 from published guidelines, direct and indirect published clinical evidence, first hand clinical data, and expert experience and consensus were collected. The grading of recommendations assessment, development and evaluation (GRADE) method was used to grade the evidence and make the recommendations. RESULTS: Based on the available evidence, the guidelines recommended 17 Chinese medicines for COVID-19: 2 Chinese herbal granules, 7 Chinese patent medicines, and 8 Chinese herbal injections. CONCLUSION: As the literature search was conducted on March, any subsequent versions of these guidelines require an up-to-date literature review. We hope that the evidence summary in these will be helpful in global efforts to address COVID-19.


Subject(s)
Drugs, Chinese Herbal/therapeutic use , Medicine, Chinese Traditional/methods , COVID-19/drug therapy , Humans , SARS-CoV-2/pathogenicity
6.
Am J Chin Med ; 48(7): 1511-1521, 2020.
Article in English | MEDLINE | ID: covidwho-910319

ABSTRACT

The worldwide spread of the 2019 novel coronavirus has become a profound threat to human health. As the use of medication without established effectiveness may result in adverse health consequences, the development of evidence-based guidelines is of critical importance for the clinical management of coronavirus disease (COVID-19). This research presents methods used to develop rapid advice guidelines on treating COVID-19 with traditional Chinese medicine (TCM). We have followed the basic approach for developing WHO rapid guidelines, including preparing, developing, disseminating and updating each process. Compared with general guidelines, this rapid advice guideline is unique in formulating the body of evidence, as the available evidence for the treatment of COVID-19 with TCM is from either indirect or observational studies, clinical first-hand data together with expert experience in patients with COVID-19. Therefore, our search of evidence not only focuses on clinical studies of treating COVID-19 with TCM but also of similar diseases, such as pneumonia and influenza. Grading of recommendations assessment, development and evaluation (GRADE) methodology was adopted to rate the quality of evidence and distinguish the strength of recommendations. The overall certainty of the evidence is graded as either high, moderate, low or very low, and to give either "strong" or "weak" recommendations of each TCM therapy. The output of this paper will produce the guideline on TCM for COVID-19 and will also provide some ideas for evidence collection and synthesis in the future development of rapid guidelines for COVID-19 in TCM as well as other areas.


Subject(s)
COVID-19/drug therapy , Drugs, Chinese Herbal/therapeutic use , Medicine, Chinese Traditional/methods , Practice Guidelines as Topic , SARS-CoV-2/drug effects , COVID-19/epidemiology , COVID-19/virology , Humans , Pandemics/prevention & control , SARS-CoV-2/physiology
7.
SSRN; 2020.
Preprint | SSRN | ID: ppcovidwho-1851

ABSTRACT

Background: Few studies have examined the association between treatment given time and clinical outcomes, which is indeed of great importance to clinical manage

8.
Chin. J. Med. Imaging Technol. ; 3(36): 415-419, 20200320.
Article in Chinese | WHO COVID, ELSEVIER | ID: covidwho-142055

ABSTRACT

Objective: To observe clinical and imaging manifestations of family clustering corona virus disease 2019 (COVID-19). Methods: Data of 16 COVID-19 patients from 7 groups of families were enrolled, and the family epidemiological history, onset time, clinical symptoms and imaging manifestations were retrospectively analyzed. Results: Positive findings of the first X-ray films existed in 9 cases, negative in 5 cases, while 2 cases were found with suspicious pneumonia. Positive CT findings were observed in 15 cases, including 12 with bilateral lung lesions and 3 with lesions in unilateral lung, while 1 case was found without abnormality. Pure ground glass opacities (GGO) were detected in 4 cases, pure small nodule in 1 case, coexisting of GGO, consolidation and nodule in 11 cases. Pericardial effusion was noticed in 1 case, pleural and interlobar pleural thickening in 4 cases, and small amount of pleural effusion in 1 case. After effective treatment, lesions were absorbed more than 50% in 12 (12/15,80.00%) patients, whereas residual lesions were still observed in 14 patients. Conclusion: Family clustering corona virus disease 2019 (COVID-19) has certain clinical characteristics. Combined with epidemiology and clinical symptoms, CT has important role in screening, early diagnosis, evaluation and follow-up of COVID-19.

SELECTION OF CITATIONS
SEARCH DETAIL